Information Provided By: 
Fly News Breaks for January 7, 2019
NBIX
Jan 7, 2019 | 06:04 EDT
Neurocrine Biosciences preannounced Q4 Ingrezza sales of $130M, compared to the Street estimate of $123M, Piper Jaffray analyst David Amsellem tells investors in a research note. The analyst continues to believe that "high visibility" into continued volume and sales growth for Ingrezza in tardive dyskinesia "points to ample room for value recovery and sustainable value creation." He reiterates an Overweight rating on shares of Neurocrine with a $111 price target.
News For NBIX From the Last 2 Days
There are no results for your query NBIX
